Register Now - Beyond Recruitment: The Future of Patient Site Engagement in Oncology Clinical Trials
Logo Image
|Articles|March 12, 2015

Biomedical Systems Launches Next Generation eCOA Technology

Biomedical Systems, a premier global provider of centralized diagnostic services, launches its second generation clinical outcome assessment software offering three easy-to-use platforms to collect patient data.

Biomedical Systems, a global provider of centralized diagnostic services, launched its second generation clinical outcome assessment software offering three platforms to collect patient data: the home, investigative site and the web. In addition, the Android smartphone is part of the home technology and the Android tablet is used at the site. Biomedical Systems provides eCOA technology along with cardiac safety, pulmonary function and imaging centralized diagnostic services.

 

The second version eCOA technology, updating the first which launched in January 2013, now includes the following features:

  •  More flexible software

  •  Improved compliance

  •  Improved ease of use for both sites and patients

  • More reliable data transmission 

 

Read the full release here. 

Related to this article

View more
Closing the Community Access Gap: Q&A with Kent Thoelke, Paradigm Health
Closing the Community Access Gap: Q&A with Kent Thoelke, Paradigm Health
In this Q&A, Kent Thoelke, CEO of Paradigm Health, discusses why participation gaps in community and rural settings come down to both patient cost barriers and site infrastructure, how legacy workflows weigh on community clinics, and what policy and technology changes it would take to make clinical research a real care option for more patients.
Read more
© Grispb - © Grispb - stock.adobe.com
Comparing OpenAI and Mistral on Clinical Trial Matching
Mistral and OpenAI produced identical overall eligibility labels across 200 synthetic patient-study assessments, with criterion-level disagreements concentrated in inclusion criteria where models switch between “Uncertain” and “Not included” when records lack sufficient evidence, so model choice should be driven by deployment architecture, control, and cost rather than assumed interchangeability.
Read more
The Human Side of Clinical Trials: Before Burden Becomes Risk, Capturing Friction in Real Time
The Human Side of Clinical Trials: Before Burden Becomes Risk, Capturing Friction in Real Time
In Episode 4 of The Human Side of Clinical Trials, host Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., speaks with Jason Riis, PhD, CEO and chief behavioral scientist at Behavioralize, about how capturing friction closer to the moment it happens can reveal unclear instructions, technology friction, and workarounds that retrospective surveys and debriefs tend to miss.
Read more